Ceftriaxona [Inn-Spanish] en es it fr

Ceftriaxona [Inn-Spanish] Brand names, Ceftriaxona [Inn-Spanish] Analogs

Ceftriaxona [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Ceftriaxona [Inn-Spanish] Chemical_Formula


Ceftriaxona [Inn-Spanish] RX_link


Ceftriaxona [Inn-Spanish] fda sheet

Ceftriaxona_[Inn-Spanish] FDA

Ceftriaxona [Inn-Spanish] msds (material safety sheet)

Ceftriaxona_[Inn-Spanish] MSDS

Ceftriaxona [Inn-Spanish] Synthesis Reference

M. Montavon, R. Reiner, Brit. pat. Appl. 2,022,090; eidem, U.S. pat. 4,327,210 (1979, 1982 both to Hoffmann-La Roche)

Ceftriaxona [Inn-Spanish] Molecular Weight

554.583 g/mol

Ceftriaxona [Inn-Spanish] Melting Point

>155 oC

Ceftriaxona [Inn-Spanish] H2O Solubility

No information avaliable

Ceftriaxona [Inn-Spanish] State


Ceftriaxona [Inn-Spanish] LogP


Ceftriaxona [Inn-Spanish] Dosage Forms

IM infusion;

Ceftriaxona [Inn-Spanish] Indication

For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

Ceftriaxona [Inn-Spanish] Pharmacology

Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ceftriaxone results from the inhibition of cell wall synthesis and is mediated through Ceftriaxone binding to penicillin binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Ceftriaxona [Inn-Spanish] Absorption

No information avaliable

Ceftriaxona [Inn-Spanish] side effects and Toxicity

No information avaliable

Ceftriaxona [Inn-Spanish] Patient Information

Patient Information:

Patients should be counseled that antibacterial drugs including Ceftriaxone should only be used to
treat bacterial infections. They do not treat viral infections (eg, common cold). When Ceftriaxone
is prescribed to treat a bacterial infection, patients should be told that although it is common
to feel better early in the course of therapy, the medication should be taken exactly as directed.
Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of
the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and
will not be treatable by Ceftriaxone or other antibacterial drugs in the future.

Ceftriaxona [Inn-Spanish] Organisms Affected

Enteric bacteria and other eubacteria